[Effects of monoclonal antibody cetuximab on proliferation of non-small cell lung cancer cell lines].
OBJECTIVE
The epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab has been used widely in non-small cell lung cancer patients. The aim of this study is to explore the effect of lung cancer cells (A549, H460, H1299, SPC-A-1) which were treated by cetuximab in vitro.


METHODS
We studied the effects of increasing concentrations of cetuximab (1 nmol/L-625 nmol/L) in four human lung cancer cell lines (A549, SPC-A-1, H460, H1229). CCK8 measured the inhibition of cell proliferation in each group. A549, SPC-A-1 were marked by PI and the statuses of apoptosis were observed. Western blot were used to detect the proliferation-related signaling protein and apoptosis-related protein in A549.


RESULTS
The treatment with cetuximab resulted in the effect on cell proliferation and apoptosis in a time- and dosedependent manner. The expression of activated key enzymes (p-AKT, p-EGFR, p-MAPK) in EGFR signaling transduction pathway were down-regulated more obviously.


CONCLUSIONS
Cetuximab is an effective targeted drug in the treatment of lung cancer cell lines, tissues, most likely to contribute to the inhibition of key enzymes in EGFR signaling transduction pathway.
Chen
Zhen
Z
Department of Pathology, Shidong Hospital, Shanghai Jiaotong University, Shanghai 200438, China.
Chen
Zhiwei
Z
D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D017209:Apoptosis / Q000187:drug effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D000068818:Cetuximab; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology*; D015398:Signal Transduction / Q000187:drug effects
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068818:Cetuximab